Novo Nordisk has various long-standing US affordability offerings for eligible people living with diabetes. Credit: Novo Nordisk A/S.

Novo Nordisk has announced plans to reduce the US wholesale acquisition cost (WAC), also known as the list price, of several pre-filled insulin pens and vials by up to 75% for people living with type 1 and type 2 diabetes.

Set to come into effect from 1 January 2024, these changes will be applicable for products including pre-filled pens and vials of basal (long-acting), bolus (short-acting) and pre-mix insulins, Levemir, Novolin, NovoLog and NovoLog Mix 70/30 in specific.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Novo Nordisk Market Access & Public Affairs senior vice-president Steve Albers said: “We have been working to develop a sustainable path forward that balances patient affordability, market dynamics, and evolving policy changes.

“Novo Nordisk remains committed to ensuring patients living with diabetes can afford our insulins, a responsibility we take seriously.”

The company will reduce the list price of four legacy insulin brands, including NovoLog and NovoLog Mix 70/30 by 75%, and Novolin and Levemir by 65% off the current list price.

Additionally, the list price of unbranded biologics (pre-filled pens and vials and pre-mix insulins) is being reduced to match the lowered price of each respective branded insulin (Insulin Aspart and Insulin Aspart Protamine/Insulin Aspart).

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Novo Nordisk also has various long-standing US affordability offerings for eligible people who are living with diabetes.

They include Unbranded Biologics, the Novo Nordisk Human Insulin programme, Co-pay Savings Cards, My$99Insulin, Immediate Supply, A Patient Assistance Program (PAP) and the Covid-19 Patient Assistance Program.

Working with a diverse group of stakeholders, Novo Nordisk said it will understand the emerging needs of patients.